LEHI, UT, June 30, 2022 – Civica, Inc. (Civica Rx) announced today it has joined a new coalition of diverse stakeholders to address drug shortages in the United States. The End Drug Shortages Alliance provides a forum for key stakeholders to take strategic aim at one of health care’s more pressing and enduring issues, drug shortages that disrupt patient care.

Over the past two decades, shortages of generic drugs critical to the lifesaving work of hospitals in our country have become far too commonplace. Today, hospitals and health care systems now maintain permanent drug shortage response teams that seek alternatives to unavailable drugs.

Civica is pleased to be a part of this important Alliance. It is consistent with our work to solve this unacceptable problem by bringing stability, predictability, affordability, and transparency back to the supply of quality generic medications that are so crucial for patients around the country.

The End Drug Shortages Alliance was launched in late 2021 to bring together industry stakeholders, including providers, group purchasing organizations, manufacturers, distributors and other industry thought leaders and champions. Efforts will focus on improving access to medications through greater transparency across market participants, leading to improved quality manufacturing of medications and production of additional supply.

"We are grateful to have Civica join the alliance to end drug shortages," said Eric Tichy, division chair of pharmacy supply solutions for Mayo Clinic, who serves as the Chair for the Alliance advisory board. "Collaboration among organizations strengthens our ability to improve the quality of life for patients that rely on these medications. Together, we can make a difference."


###

**About End Drug Shortages Alliance**

The End Drugs Shortages Alliance is a collaboration of select health systems, supply chain, industry and other stakeholders including group purchasing organizations, manufacturers, distributors and other industry thought leaders dedicated to solving the pharmaceutical supply challenges that disrupt access to essential medications in the U.S. We prioritize initiatives focused on transparency, quality, redundancy and production of additional supply to achieve undisrupted access to essential medications for health care providers and patients.